The usefulness of Tc-99m MIBI for evaluating brain tumors: Comparative study with Tl-201 and relation with P-glycoprotein

Clinical Nuclear Medicine

Volumn 24, Issue 10, 1999, Pages 765-772

  Nagamachi, Shigeki ^a   Jinnouchi, Seishi ^a   Ohnishi, Takashi ^a   Nakahara, Hiroshi ^a   Flores II, Leo ^a   Tamura, Shozo ^a   Yokogami, Kiyotaka ^a   Kawano, Hirokazu ^a   Wakisaka, Shinnichiro ^a  

^a UNIVERSITY OF MIYAZAKI   (Japan)

Author keywords

Brain Tumor; P glycoprotein; Prediction of Therapeutic Effect; Tc 99 MIBI; Tl 201

Indexed keywords

GLYCOPROTEIN P; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; THALLIUM 201;

ADULT; AGED; ARTICLE; BRAIN SCINTISCANNING; BRAIN TUMOR; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; GLIOBLASTOMA; HUMAN; IMAGE QUALITY; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; TUMOR VOLUME;

EID: 0032839994     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003072-199910000-00007     Document Type: Article

References (33)

1. Kaplan WD, Takvorian T, Morris JH, et al: Thallium-201 brain tumor imaging: A comparative study with pathologic Correlation. J Nucl Med 28:47, 1987.
2. Tamura M, Shibasaki T, Zama A, et al: Assessment of malignancy of glioma by positron emission tomography with 18F-fluorode-oxyglucose and single photon emission computed tomography with thallium-201 chloride. Neurosurgery 40:210, 1998.
3. Yoshii Y, Satou M, Yamamoto T, et al: Experimental evaluation of the usefulness of thallium-201 single photon emission tomography in the investigation and characterization of brain tumors in man and their response to treatment. Eur J Nucl Med 20:39, 1993.
4. Oriuchi N, Tamura M, Shibazaki T, et al: Clinical evaluation of thallium-201 SPECT in supratentorial gliomas: Relationship to histologic grade, prognosis and proliferative activities. J Nucl Med 34:2085, 1993.
5. Jinnouchi S, Hoshi H, Ohnishi T, et al: Thallium-201 SPECT for predicting histological types of meningioma. J Nucl Med 34: 2091, 1993.
6. Abrams MJ, Davison A, Jones AG, et al: Synthesis and characterization of Hexakis (alkyl isocyanide) complex of technetium (I). Inorg Chem 22:2798, 1983.
7. Nishiyama Y, Kawasaki Y, Yamamoto Y, et al: Technetium-99m-MIBI and thallium-201 scintigraphy of primary lung cancer. J Nucl Med 38:1358, 1997.
8. Hassan IM, Sahweil A, Constantinides C, et al: Uptake and kinetics of Tc-99m hexakis-2-methoxy-isobutyl-isonitrile in benign and malignant lesions in the lungs. Clin Nucl Med 14:333, 1989.
9. 201TI and relation to chemotherapeutic effect. Kakuigaku 34:453, 1997.
10. Learoyd DL, Roach PJ, Briggs GM, et al: Technetium-99m-sestamibi scanning recurrent medullary thyroid carcinoma. J Nucl Med 38:227, 1997.
11. Kapucu LO, Akyuz C, Vural G, et al: Evaluation of therapy response in children with untreated malignant lymphomas using technetium-99m-sestamibi. J Nucl Med 38:243, 1997.
12. Chiu M, Kronauge J, Piwnica-Worms D: Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis (2-methoxyisobutylisonitile) technetium (I) in cultured mouse fibroblasts. J Nucl Med 31:1646, 1990.
13. Piwnica-Worms D, Holmans B: Editorial: Non-cardiac application of hexakis-(alkylisonitrile) technetium-99m-complexes. J Nucl Med 31:1166, 1990.
14. 201TI and predictivity of therapeutic effect. Kakuigaku 35:121, 1998.
15. 99mTc-sestamibi SPET? Eur J Nucl Med 25:401, 1998.
16. Baillet G, Albuquerque L, Chen Q, et al: Evaluation of single-photon emission tomography imaging of supratentorial brain gliomas with technetium-99m sestamibi. Eur J Nucl Med 21: 1061-1066, 1994.
17. 99mTc-sestamibi. Nucl Med Commun 16:258, 1995.
18. O'Tuama LA, Trevers ST, Larar JN, et al: Thallium-201 versus technetium-99m-MIBI SPECT in evaluation of childhood brain tumors: A within-subject comparison. J Nucl Med 34:1045, 1993.
19. Shin WJ, Kadzielawa K, Lee C, et al: Tc-99m sestamibi uptake by cerebellar metastasis from bronchogenic carcinoma. Clin Nucl Med 18:887, 1993.
20. Packard AB, Kronauge JF, Limpa AN, et al: Tumor uptake of 99mTc-MIBI and 201TI by a 9L gliosarcoma brain tumor model in rats. Nucl Med Biol 20:773, 1993.
21. Andrews DW, Das R, Kim S, et al: Technetium-MIBI as a glioma imaging agent for the assessment of multi-drug resistance. Neurosurgery 40:1323, 1997.
22. Maffioli L, Gasparini M, Chiti A, et al: Clinical role of technetium-99m sestamibi single-photon emission tomography in evaluating pretreated patients with brain tumors. Eur J Nucl Med 23:308, 1996.
23. Piwnica WD, Chiu ML, Budding M, et al: Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res 53: 977, 1993.
24. Luker GD, Fracasso PM, Dobkin J, et al: Modulation of the multidrug resistance P-glycoprotein: Detection with technetium-99m-sestamibi in vivo. J Nucl Med 38:369, 1997.
25. Kostakoglu L, Elahi N, Kïratlï P, et al: Clinical validation of the influence of P-glycoprotein on technetium-99m-sestamibi uptake in malignant tumors. J Nucl Med 38:1003, 1997.
26. Francavilla TL, Miletich RS, Di Chiro G, et al: Positron emission tomography in the detection of malignant degeneration of low-grade gliomas. Neurosurgery 24:1, 1989.
27. Chamberlain MC, Murovic JA, Levin VA: Absence of contrast enhancement on CT brain scans of patients with supratentorial malignant gliomas. Neurology 38:1371, 1988.
28. 201TI in a tumor cell line. Nucl Med Commun 18:235, 1997.
29. Chen LB: Mitochondrial membrane potential in living cells. Annu Rev Cell Biol 4:155, 1988.
30. Cordon CC, O'Brien JP, Casals D, et al: Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 86:695, 1989.
31. Feun LG, Savaraj N, Landy HJ: Drug resistance in brain tumors. J Neurooncol 20:165, 1994.
32. Kabasakal L, Ozker K, Hayward M, et al: Technetium-99m sestamibi uptake in human breast carcinoma cell lines displaying glutathione-associated drug-resistance. Eur J Nucl Med 23:568, 1996.
33. Moretti JL, Cordobes MD, Starzec A, et al: Involvement of glutathione in loss of technetium-99m-MIBI accumulation related to membrane MDR protein expression in tumor cells. J Nucl Med 39:1214, 1998. (Zymed Laboratories, South San Francisco, CA